AtriCure, Inc. (ATRC)
After hours:
| Previous close | 22.22 |
| Open | 22.83 |
| Bid | 20.83 x 300 |
| Ask | 20.90 x 100 |
| Day's range | 20.78 - 23.01 |
| 52-week range | 20.19 - 59.61 |
| Volume | |
| Avg. volume | 783,080 |
| Market cap | 1.011B |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
AtriCure Reports First Quarter 2024 Financial Results
MASON, Ohio, May 01, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results.
- Business Wire
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
MASON, Ohio, April 30, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference.
- Business Wire
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
